About this event

Festival of Biologics Basel 2026 (Messe Basel) — Event Research & Buyer Targeting Guide

Event basics (from official event details)

• Event title: Festival of Biologics Basel 2026
• Date: 13–15 October 2026
• Venue: Hall 1, Messe Basel
• City & country: Basel, Switzerland
• Stated positioning: Europes largest biologics event

What the event covers (how the audience is structured)

Festival of Biologics Basel 2026 is positioned as a start-to-finish industry meeting for large-molecule therapies and related workflows. The event agenda focus is explicitly stated across Discovery, Development, Clinical Trials, Manufacturing, Market Access, and Fill & Finish. This matters for buyer targeting because it indicates that decision-making functions are present across the value chain: from R&D and CMC through clinical operations and into production/scale-up and commercial readiness.

The event is designed for industry experts in pharma and biotech, along with start-ups, academics, regulators, and investors. It also emphasizes a large-molecule therapy ecosystem spanning multiple modalities, including antibody therapies, cell and gene therapies, immunotherapies, and biosimilars.

1️⃣ Who attends (BUYERS / ATTENDEES)

Festival of Biologics is not only a scientific conference; it’s organized around the biologics and ATMP value chain. As a result, the most “buyer-relevant” attendees are typically those who influence vendor selection, technology adoption, service procurement, and partnership decisions. Based on the event’s described audience types and topic coverage, the strongest attendee groups generally include:

A) Industry decision-makers (primary buyer layer)

• Biologics R&D leadership: teams and leaders responsible for early discovery, modality engineering, translational programs.
• CMC and developability leaders: stakeholders who set technical strategy for biologics manufacturing feasibility, process development, and characterization.
• Clinical trials leaders: groups managing protocol development, patient safety, trial operations, and clinical development planning.
• Manufacturing and operations leaders: leaders responsible for production scale-up, process validation readiness, and operational execution.
• Fill & finish operations stakeholders: decision-makers connected to upstream/downstream integration, aseptic processing interfaces, and transfer readiness.
• Commercial and market access stakeholders: teams involved in launch readiness, access strategy, and evidence generation alignment.

B) Ecosystem participants that often become buyers through partnerships

• Start-ups (100 start-ups stated): often in vendor-evaluation mode, partnership search mode, and “technology validation” mode.
• Academics: typically influence technology direction and collaboration pipelines (less direct purchasing, but high partnership value).
• Regulators: typically shape compliance requirements, documentation standards, and evaluation frameworks.
• Investors: influence diligence priorities and selection of service providers aligned to development milestones.

C) Why buyer fit is unusually strong here

Many conferences have either “pure research” or “pure commercial” audiences. Here, the explicit agenda coverage across discovery to fill/finish and market access suggests multiple purchase cycles appear within one event: technology adoption, clinical execution, manufacturing services, and access planning. That combination improves the probability that we will find usable buyer profiles rather than only general attendees.

2️⃣ Where the show is happening + attendee geographic origin

Show location: Hall 1, Messe Basel, Basel, Switzerland.

Attendee geographic origin (high-confidence direction based on event positioning and typical biologics ecosystem patterns): Festival of Biologics Basel is positioned as “Europe’s largest biologics event,” which strongly indicates that the core attendee base is predominantly European, with substantial representation from global pharma/biotech hubs. Because the event also includes start-ups, investors, and regulators, the ecosystem tends to be international: teams in the US, UK, and Asia often participate in large-molecule and ATMP-related events for benchmarking, partner discovery, and vendor evaluation.

Best targeting geography for buyer lists (practical approach):

• Europe-first: Switzerland, Germany, UK, France, Netherlands, Nordics, and DACH-region biopharma and biotech ecosystems.
• Global secondary layer: US and UK organizations with EU-facing operations, plus APAC teams working with global partners.
• Cross-border collaboration likely: buyers frequently engage vendors and partners across regions for platform, CMC, manufacturing, and clinical delivery.

3️⃣ Audience reach (Local / National / Global)

Audience reach: Global with a strong Europe core. The event is explicitly described as Europe’s largest biologics event, and it brings a combined audience across pharma, biotech, start-ups, academics, regulators, and investors. That structure typically attracts global-facing brands and partners who need cross-region alignment.

4️⃣ Sample buyer company names (BUYERS ONLY) + websites (15–20)

Below are buyer-style companies to target for this event, aligned to the event’s stated sponsor/brand presence and the biologics ecosystem functions it covers. These are intended for buyer outreach and lead sourcing.

Important: We will match these company targets to the most relevant job titles (CMC, clinical development, manufacturing/fill-finish, market access, technical R&D, patient safety, and development leadership) for higher response rates.

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Novartis	novartis.com	VP Immunology / Global Program Head / Translational Research Lead	Officially named speaker/sponsor presence; strong alignment with discovery, translational medicine, and immunology-led biologics programs.
2	Roche	roche.com	Head of Biologics Development / Director Clinical Development	Major biologics ecosystem player; likely to evaluate vendors across clinical execution, CMC, and production readiness.
3	Sandoz	sandoz.com	Global Head of Patient Safety & Clinical Development / Biosimilars Leadership	The event explicitly covers biosimilars and clinical trials; Sandoz presence indicates relevance for safety, development, and market-facing evidence needs.
4	Merck KGaA	merckgroup.com	Biologics CMC / Developability & Process Development Director	Fit with manufacturing, CMC, and platform science; Merck’s biopharma footprint typically maps to value chain decision-makers.
5	Sanofi	sanofi.com	Director of Clinical Trials / Head of Immunotherapy Development	Direct alignment with clinical trials and large-molecule development; sponsor presence suggests active buying and partnership evaluation.
6	ETH Zurich	ethz.ch	Research Program Leadership / Translational Science Program Lead	Academic presence can create collaboration pathways and early adoption of new platforms and translational tools.
7	University Hospital Basel	usb.ch	Clinical Research Governance / Translational Medicine Program Leader	Hospital-based translational and clinical research leadership often influences clinical infrastructure and operational partner selection.
8	Pierre Fabre	pierre-fabre.com	Senior Director, Biologics CMC and Developability	Directly connected to CMC and developability roles; strong relevance to manufacturing and formulation decisions.
9	JJP Biologics	jjpbiologics.com	CSO / Chief Scientific Officer	Scientific leadership typically drives partner technology selection across discovery, engineering, and early development.
10	Tubulis	tubulis.com	VP Biology and Translational Research	Translational leadership aligns with discovery-to-clinical transitions; strong probability of vendor evaluation for clinical readiness.
11	King's College London	kcl.ac.uk	Professor of Translational Immunology / Research Program Director	Academic immunotherapy leadership supports partnerships and tool/provider alignment for translational studies.
12	KTH Royal Institute of Technology	kth.se	Professor, Antibody Technology and Directed Evolution	Antibody engineering expertise maps to discovery/modality engineering and supplier selection for specialized platforms.
13	Cimeio Tx	cimeio.com	CSO / Translational Development Leadership	CSO leadership commonly drives technology partner choices and translational roadmap decisions.
14	PK Sciences	pk-sciences.com	Director Scientific Governance / Translational & Scientific Compliance Lead	Scientific governance roles align strongly with clinical development documentation, governance frameworks, and compliance-driven decisions.
15	Formycon AG	formycon.com	CSO / Head of Biosimilars R&D	Biosimilars-focused leadership matches the event’s modality coverage; likely needs CMC/clinical evidence and vendor partners.
16	IGL (The Danish Generic and Biosimilars Medicines Industry Association)	igl.net	CEO / Industry Program Director	Industry association leadership is valuable for mapping biosimilars market access needs and ecosystem-wide partner priorities.
17	KTH / Academia-adjacent innovators (partner pipeline)	kth.se	Translational Research Collaboration Lead	When biotech needs specialized platforms, academic-adjacent leaders become important collaboration entry points.
18	University of Applied Sciences and Arts Northwestern Switzerland FHNW	fhnw.ch	Professor / Translational Research Program Lead	Regional translational and applied research can create early-stage collaboration opportunities for technology providers.

How we use this sample set: We prioritize companies where (a) the event website lists brand presence (e.g., named organizations in the page), and (b) the job functions map directly to discovery, CMC, clinical trials, manufacturing, fill/finish, and market access. Then we expand the buyer list beyond these named brands based on similarity (biologics and ATMP value-chain roles).

5️⃣ Job profiles, industries & event type

A) Best job profiles to target (high-probability buyer roles)

• Discovery & early development
  • Head / Director of Early Stage Discovery
  • Modality Engineering Lead
  • Translational Medicine Director
  • Immunology Program Leader
• Clinical trials
  • Director / VP of Clinical Development
  • Head of Patient Safety
  • Clinical Trials Program Lead
  • Global Clinical Operations Manager
• CMC & developability
  • VP / Director of Biologics CMC
  • Developability & Characterization Lead
  • Technical R&D Biologics and Cell & Gene Therapy lead
• Manufacturing, process & fill/finish
  • Manufacturing Director (Biologics)
  • Director of Process Development
  • Fill & Finish Operations Lead
  • Technical Transfer / Scale-up Lead
• Market access & commercialization evidence
  • Head of Market Access Strategy
  • Director of Commercialization Planning
  • Evidence & Outcomes Strategy Lead

B) Industries to use (mapping to an “Apollo-style” industry list)

Based on the event’s focus on antibody therapies, immunotherapies, biosimilars, ATMP, and the explicit value chain topics, the strongest industry categories to apply are:

• Pharmaceuticals
• Medical Devices (where clinical trials and therapy delivery intersect, though event emphasis is biologics)
• Biotechnology
• Hospital & Health Care (clinical research and translational stakeholders)
• Research (academia and translational research leadership)
• Events Services (only for sponsor/exhibitor ecosystem mapping, not core buyers)
• Government Administration (for regulators, if present in attendee mix)
• Market Research (only if market access evidence strategy leads are active in the buyer pool)

C) Event type (what it is, practically)

• Industry conference + technical value chain meeting
• Biologics & ATMP ecosystem conference
• Technology and service adoption catalyst (discovery → clinical → manufacturing → fill/finish → market access)
• Sponsor/exhibit expo component with exhibitors and a defined “Emerging Business Zone” (Emerging Business Zone / Startup area referenced on the site)

6️⃣ Estimated attendance (expected total footfall)

The official site states:

• Attendees: 3,000
• Speakers: 380
• Exhibitors: 150
• Start-ups: 100
• Stated ecosystem scale: “bringing together 3000+ attendees”

Buyer-density expectation: Because the event spans multiple decision layers (technical, clinical, manufacturing, market access), buyer density is typically higher than purely academic conferences. The most “buyer-efficient” segments for lead sourcing are CMC, clinical development/patient safety, technical R&D, manufacturing leadership, and market access strategy roles.

7️⃣ Key focus areas & buyer engagement (what will attract buyers)

A) Key focus areas (explicit from the event page)

• Discovery
• Development
• Clinical Trials
• Manufacturing
• Market Access
• Fill & Finish

B) Additional thematic areas mentioned

• Early stage discovery and modality engineering
• Translational medicine
• Clinical trials execution and patient safety
• Commercialization and fill/finish operations
• Across key therapy and disease areas
• Panels, roundtables, and workshops across three days

C) Buyer engagement approach (how we position outreach)

To engage the most purchase-influencing attendees, we position outreach around measurable value inside these focus areas. Examples of engagement angles that typically resonate in biologics conferences:

• Risk reduction: faster development cycles, fewer setbacks, improved predictability across CMC and clinical transitions.
• Compliance and governance: improved quality systems, documentation readiness, scientific governance frameworks.
• Operational scalability: supporting manufacturing and fill/finish integration, tech transfer readiness, and scale-up confidence.
• Evidence alignment: supporting the evidence needed for market access readiness and commercialization planning.
• Partnership acceleration: helping discovery-to-clinic conversion with platform fit and collaboration speed.

8️⃣ Client product fit & buyer targeting request (we need your website)

To select “best buyer fit” contacts aligned to your exact offering, we need the client product context. Please share your website URL (the company website for your product/service). Once we have that, we will map your solution to the event’s value chain and produce:

• Best buyer segments (e.g., discovery/CMC/clinical/manufacturing/fill/finish/market access)
• Best job titles for your specific solution category
• Priority company shortlists aligned to those titles
• Disqualification rules (to avoid mismatched audiences)

Please send: the client website link and a 2–3 sentence summary of what the product/service does (and for whom). Then we will return the most relevant buyer list strategy for this event.

9️⃣ Final recommendation (fit rating and how to proceed)

Overall fit: High fit for buyer outreach and targeted meeting scheduling, because Festival of Biologics Basel 2026 is explicitly structured around the biologics value chain and includes pharma/biotech leaders, CMC, clinical trials, manufacturing and fill/finish stakeholders—plus regulators and investors.

Best ways to focus your targeting

• Start with value-chain mapping: choose the event tracks that match your product (discovery vs CMC vs clinical vs manufacturing/fill/finish vs market access).
• Target titles aligned to procurement influence: leadership and director-level roles in CMC, clinical development, manufacturing operations, and patient safety.
• Use Europe-first geography with global overlay: Basel event context is Europe-led, but biologics companies operate globally.
• Leverage sponsor/brand gravity: the event page lists major organizations and speaker brands; we use that to seed the highest-likelihood accounts.

Quality scoring (practical execution view)

• Buyer relevance: Strong
• Account likelihood: Strong (many named pharma/biotech entities)
• Title relevance: Strong if we filter to the value-chain functions listed above
• Execution risk: Moderate only if we don’t align your product to the correct value-chain stage

---

Next step (required from you)

Please share your client website so we can identify the best buyer segments and produce a refined buyer list matching your exact offering and messaging.